Ravshan I. Ataullakhanov
Research Subjects
Ravshan I. Ataullakhanov has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Aleksei V. Pichugin
NRC Institute of Immunology FMBA of Russia, 24 Kashirskoe shosse, 115472 Moscow, Russia
16 shared publications - Ekaterina Lebedeva
National Research Center Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, Russia
13 shared publications - E.I. Ushakova10 shared publications
- Alexander Bagaev
BostonGene Corporation, Waltham, Massachusetts
7 shared publications - Denis Yu. Logunov
Federal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named After Honorary Academician N. F. Gamaleya”, the Ministry of Health of the Russian Federation, Moscow 123098, Russia
5 shared publications - Marina Chulkina
Ministry of Health of the Russian Federation
5 shared publications
Latest Publications
- 17 August 2025
- Published by Pleiades Publishing Ltd in Biology Bulletin Reviews
- Vol. 15 (4) , 607-622
Echo of Carcino-Evo-Devo. On the Beneficial Role of Inherited Tumors in the Evolution of Organisms
The analytical article critically examines some aspects of the theory of carcino-evo-devo, testing its strength, which is known to be useful for strengthening and improving both new and long-established ideas in the scientific world. A.P. Kozlov, a true alpha scientist, like a powerful actively moving object, created a stream that for decades attracted and carried away associates and like-minded people. I am sure that the participants of this journey not only overcame difficulties but also enjoyed a real scientific search, an exciting adventure in the world of living beings, genes, molecules, cells, and organisms—the fantasy world in the imagination of a scientific researcher, where the knowledge of the real world takes place, as well as the exploration of the unknown, the expansion of our ideas about the living, and the understanding of how this world develops and how a wonderful variety of life arose, including ourselves. In all this, I see the value of A.P. Kozlov’s work and his theory of carino-evo-devo.
- 17 August 2025
- Published by Pleiades Publishing Ltd in Biology Bulletin Reviews
- Vol. 15 (4) , 607-622
Echo of Carcino-Evo-Devo. On the Beneficial Role of Inherited Tumors in the Evolution of Organisms
The analytical article critically examines some aspects of the theory of carcino-evo-devo, testing its strength, which is known to be useful for strengthening and improving both new and long-established ideas in the scientific world. A.P. Kozlov, a true alpha scientist, like a powerful actively moving object, created a stream that for decades attracted and carried away associates and like-minded people. I am sure that the participants of this journey not only overcame difficulties but also enjoyed a real scientific search, an exciting adventure in the world of living beings, genes, molecules, cells, and organisms—the fantasy world in the imagination of a scientific researcher, where the knowledge of the real world takes place, as well as the exploration of the unknown, the expansion of our ideas about the living, and the understanding of how this world develops and how a wonderful variety of life arose, including ourselves. In all this, I see the value of A.P. Kozlov’s work and his theory of carino-evo-devo.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 46 (6)
Experimental models based on human PD1+-T cell culture for screening new immune checkpoint inhibitors
Экспериментальные модели на основе культуры PD1+- Т-клеток человека для скрининга новых ингибиторов иммунных контрольных точек
- 1 January 2025
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 46 (6)
Open AccessExperimental models based on human PD1+-T cell culture for screening new immune checkpoint inhibitors
Экспериментальные модели на основе культуры PD1+- Т-клеток человека для скрининга новых ингибиторов иммунных контрольных точек
- Open Access
- 29 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (15) , 4035-4049
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
Personalized cancer vaccines designed to target neoantigens represent a promising new treatment paradigm in oncology. In contrast to classical idiotype vaccines, we hypothesized that “polyvalent” vaccines could be engineered for the personalized treatment of follicular lymphoma (FL) using neoantigen discovery by combined whole-exome sequencing (WES) and RNA sequencing (RNA-seq). Fifty-eight tumor samples from 57 patients with FL underwent WES and RNA-seq. Somatic and B-cell clonotype neoantigens were predicted and filtered to identify high-quality neoantigens. B-cell clonality was determined by the alignment of B-cell receptor (BCR) CDR3 regions from RNA-seq data, grouping at the protein level, and comparison with the BCR repertoire from healthy individuals using RNA-seq data. An average of 52 somatic mutations per patient (range, 2-172) were identified, and ≥2 (median, 15) high-quality neoantigens were predicted for 56 of 58 FL samples. The predicted neoantigen peptides were composed of missense mutations (77%), indels (9%), gene fusions (3%), and BCR sequences (11%). Building off of these preclinical analyses, we initiated a pilot clinical trial using personalized neoantigen vaccination combined with PD-1 blockade in patients with relapsed or refractory FL (#NCT03121677). Synthetic long peptide vaccines targeting predicted high-quality neoantigens were successfully synthesized for and administered to all 4 patients enrolled. Initial results demonstrate feasibility, safety, and potential immunologic and clinical responses. Our study suggests that a genomics-driven personalized cancer vaccine strategy is feasible for patients with FL, and this may overcome prior challenges in the field. This trial was registered at www.ClinicalTrials.gov as #NCT03121677.
- 29 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (15) , 4035-4049
Open AccessNeoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
Personalized cancer vaccines designed to target neoantigens represent a promising new treatment paradigm in oncology. In contrast to classical idiotype vaccines, we hypothesized that “polyvalent” vaccines could be engineered for the personalized treatment of follicular lymphoma (FL) using neoantigen discovery by combined whole-exome sequencing (WES) and RNA sequencing (RNA-seq). Fifty-eight tumor samples from 57 patients with FL underwent WES and RNA-seq. Somatic and B-cell clonotype neoantigens were predicted and filtered to identify high-quality neoantigens. B-cell clonality was determined by the alignment of B-cell receptor (BCR) CDR3 regions from RNA-seq data, grouping at the protein level, and comparison with the BCR repertoire from healthy individuals using RNA-seq data. An average of 52 somatic mutations per patient (range, 2-172) were identified, and ≥2 (median, 15) high-quality neoantigens were predicted for 56 of 58 FL samples. The predicted neoantigen peptides were composed of missense mutations (77%), indels (9%), gene fusions (3%), and BCR sequences (11%). Building off of these preclinical analyses, we initiated a pilot clinical trial using personalized neoantigen vaccination combined with PD-1 blockade in patients with relapsed or refractory FL (#NCT03121677). Synthetic long peptide vaccines targeting predicted high-quality neoantigens were successfully synthesized for and administered to all 4 patients enrolled. Initial results demonstrate feasibility, safety, and potential immunologic and clinical responses. Our study suggests that a genomics-driven personalized cancer vaccine strategy is feasible for patients with FL, and this may overcome prior challenges in the field. This trial was registered at www.ClinicalTrials.gov as #NCT03121677.
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (4)
Experimental model of ligands to immune checkpoint receptor interaction on the example of PD1 and PD-L1
Экспериментальная модель взаимодействия лигандов с рецепторами иммунных контрольных точек на примере PD1 и PD-L1
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (4)
Open AccessExperimental model of ligands to immune checkpoint receptor interaction on the example of PD1 and PD-L1
Экспериментальная модель взаимодействия лигандов с рецепторами иммунных контрольных точек на примере PD1 и PD-L1
- 25 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (680) , 14
Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma
Severe and prolonged lymphopenia frequently occurs in patients with glioblastoma after standard chemoradiotherapy and has been associated with worse survival, but its underlying biological mechanism is not well understood. To address this, we performed a correlative study in which we collected and analyzed peripheral blood of patients with glioblastoma ( n = 20) receiving chemoradiotherapy using genomic and immune monitoring technologies. RNA sequencing analysis of the peripheral blood mononuclear cells (PBMC) showed an elevated concentration of myeloid-derived suppressor cell (MDSC) regulatory genes in patients with lymphopenia when compared with patients without lymphopenia after chemoradiotherapy. Additional analysis including flow cytometry and single-cell RNA sequencing further confirmed increased numbers of circulating MDSC in patients with lymphopenia when compared with patients without lymphopenia after chemoradiotherapy. Preclinical murine models were also established and demonstrated a causal relationship between radiation-induced MDSC and systemic lymphopenia using transfusion and depletion experiments. Pharmacological inhibition of MDSC using an arginase-1 inhibitor (CB1158) or phosphodiesterase-5 inhibitor (tadalafil) during radiation therapy (RT) successfully abrogated radiation-induced lymphopenia and improved survival in the preclinical models. CB1158 and tadalafil are promising drugs in reducing radiation-induced lymphopenia in patients with glioblastoma. These results demonstrate the promise of using these classes of drugs to reduce treatment-related lymphopenia and immunosuppression.
- 25 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (680) , 14
Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma
Severe and prolonged lymphopenia frequently occurs in patients with glioblastoma after standard chemoradiotherapy and has been associated with worse survival, but its underlying biological mechanism is not well understood. To address this, we performed a correlative study in which we collected and analyzed peripheral blood of patients with glioblastoma ( n = 20) receiving chemoradiotherapy using genomic and immune monitoring technologies. RNA sequencing analysis of the peripheral blood mononuclear cells (PBMC) showed an elevated concentration of myeloid-derived suppressor cell (MDSC) regulatory genes in patients with lymphopenia when compared with patients without lymphopenia after chemoradiotherapy. Additional analysis including flow cytometry and single-cell RNA sequencing further confirmed increased numbers of circulating MDSC in patients with lymphopenia when compared with patients without lymphopenia after chemoradiotherapy. Preclinical murine models were also established and demonstrated a causal relationship between radiation-induced MDSC and systemic lymphopenia using transfusion and depletion experiments. Pharmacological inhibition of MDSC using an arginase-1 inhibitor (CB1158) or phosphodiesterase-5 inhibitor (tadalafil) during radiation therapy (RT) successfully abrogated radiation-induced lymphopenia and improved survival in the preclinical models. CB1158 and tadalafil are promising drugs in reducing radiation-induced lymphopenia in patients with glioblastoma. These results demonstrate the promise of using these classes of drugs to reduce treatment-related lymphopenia and immunosuppression.
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (6)
Severe polypous rhinosinusitis associated with non-allergic bronchial asthma
Тяжелое течение полипозного риносинусита, ассоциированного с неаллергической бронхиальной астмой
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (6)
Open AccessSevere polypous rhinosinusitis associated with non-allergic bronchial asthma
Тяжелое течение полипозного риносинусита, ассоциированного с неаллергической бронхиальной астмой
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (5)
Study of the antigenic specificity of T-cell immune reactions in response to immunization of laboratory mice with a recombinant adenoviral vector encoding the Spike-protein of SARS-CoV-2
Исследование антигенной специфичности Т-клеточных иммунных реакций в ответ на иммунизацию лабораторных мышей рекомбинантным аденовирусным вектором,
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (5)
Open AccessStudy of the antigenic specificity of T-cell immune reactions in response to immunization of laboratory mice with a recombinant adenoviral vector encoding the Spike-protein of SARS-CoV-2
Исследование антигенной специфичности Т-клеточных иммунных реакций в ответ на иммунизацию лабораторных мышей рекомбинантным аденовирусным вектором,
- Open Access
A Multi-scale, Multiomic Atlas of Human Normal and Follicular Lymphoma Lymph Nodes
SUMMARY: Reference atlases, molecular and spatial maps of mammalian tissues, are critical resources for discovery efforts and translational research. Their utility is dependent on operationalizing the resulting data by identifying cell types, histological patterns, and predictive biomarkers underlying health and disease. The human lymph node (LN) offers a compelling use case because of its importance in immunity, structural and cellular diversity, and neoplastic involvement. One hematological malignancy, follicular lymphoma (FL), evolves from developmentally blocked germinal center B cells residing in and trafficking through these tissues. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Here, we present an integrated portrait of healthy and FL LNs using multiple genomic and advanced imaging technologies. By leveraging the strengths of each platform, we identified several tumor-specific features and microenvironmental patterns enriched in individuals who experience early relapse, the most high-risk of FL patients.
Open AccessA Multi-scale, Multiomic Atlas of Human Normal and Follicular Lymphoma Lymph Nodes
SUMMARY: Reference atlases, molecular and spatial maps of mammalian tissues, are critical resources for discovery efforts and translational research. Their utility is dependent on operationalizing the resulting data by identifying cell types, histological patterns, and predictive biomarkers underlying health and disease. The human lymph node (LN) offers a compelling use case because of its importance in immunity, structural and cellular diversity, and neoplastic involvement. One hematological malignancy, follicular lymphoma (FL), evolves from developmentally blocked germinal center B cells residing in and trafficking through these tissues. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Here, we present an integrated portrait of healthy and FL LNs using multiple genomic and advanced imaging technologies. By leveraging the strengths of each platform, we identified several tumor-specific features and microenvironmental patterns enriched in individuals who experience early relapse, the most high-risk of FL patients.
- 1 January 2022
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 43 (6)
Reprogramming of myeloid cells of the tumor microenvironment increases the efficiency of CTLA-4 and PD-1 blockade in experimental malignant melanoma immunotherapy
Перепрограммирование миелоидных клеток опухолевого микроокружения повышает эффективность блокады рецепторов CTLA-4 и PD-1 при иммунотерапии
- 1 January 2022
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 43 (6)
Reprogramming of myeloid cells of the tumor microenvironment increases the efficiency of CTLA-4 and PD-1 blockade in experimental malignant melanoma immunotherapy
Перепрограммирование миелоидных клеток опухолевого микроокружения повышает эффективность блокады рецепторов CTLA-4 и PD-1 при иммунотерапии